Simonini Gabriele, Bracaglia Claudia, Cattalini Marco, Taddio Andrea, Brambilla Alice, De Libero Cinzia, Pires Marafon Denise, Caputo Roberto, Cimaz Rolando
From the Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence; Ophthalmology Unit, Anna Meyer Children's Hospital, Florence; Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome; Pediatric Immunology and Rheumatology Unit, Brescia; Institute of Child Health and Maternal Health IRCCS Burlo Garofolo; University of Trieste, Trieste, Italy.
G. Simonini, MD, Associate Professor, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence; C. Bracaglia, MD, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS; M. Cattalini, MD, Pediatric Immunology and Rheumatology Unit; A. Taddio, MD, Institute of Child Health and Maternal Health IRCCS Burlo Garofolo, and University of Trieste; A. Brambilla, MD, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence; C. De Libero, MD, Ophthalmology Unit, Anna Meyer Children's Hospital; D. Pires Marafon, MD, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS; R. Caputo, MD, Ophthalmology Unit, Anna Meyer Children's Hospital; R. Cimaz, MD, Associate Professor, Rheumatology Unit, Anna Meyer Children's Hospital-NEUROFARBA Department, University of Florence.
J Rheumatol. 2017 Jun;44(6):822-826. doi: 10.3899/jrheum.161336. Epub 2017 Apr 1.
To identify clinical predictors of relapse in childhood autoimmune chronic uveitis after stopping systemic treatment.
A retrospective, multicenter, cohort study.
Ninety-four children in remission, receiving no treatments and with at least a 6-month followup, were enrolled. A higher probability of maintaining remission after discontinuing treatment was shown in idiopathic compared with juvenile idiopathic arthritis uveitis (Mantel-Cox chi-square = 23.21) if inactivity had been obtained within 6 months from starting systemic treatment (Mantel-Cox chi-square = 24.17) and by antitumor necrosis factor-α treatment (Mantel-Cox chi-square = 6.43).
Type of disease, time, and type of systemic therapy to achieve inactivity predict different duration of uveitis remission after treatment withdrawal.
确定停止全身治疗后儿童自身免疫性慢性葡萄膜炎复发的临床预测因素。
一项回顾性、多中心队列研究。
纳入94名处于缓解期、未接受治疗且随访至少6个月的儿童。与青少年特发性关节炎葡萄膜炎相比，特发性葡萄膜炎在开始全身治疗后6个月内达到静止状态（Mantel-Cox卡方检验=24.17）以及接受抗肿瘤坏死因子-α治疗（Mantel-Cox卡方检验=6.43）时，停药后维持缓解的可能性更高（Mantel-Cox卡方检验=23.21）。
疾病类型、达到静止状态的时间和全身治疗类型可预测停药后葡萄膜炎缓解的不同持续时间。
